response from martin rogers, page-31

I understand erahs.

While my view with the current situation re N listing is that SEC has the decision making position here and we will have to comply with what they require us to do prior to listing, that's not to talk about it in high profile manner, hence no mention in the newsletter, but still could answer individual query.

N listing would be a major step in Prima's development pineline, while I'm not particular concern about its immediate timeframe, rather I have more interest in the data from the upcoming trials.